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Abstract
Background: Many experimental data evidence that over-expression of various growth factors cause disorders in cell
proliferation. The role of the Fibroblast Growth Factors (FGF) in growth control is indisputable: in particular, FGF1 and its
tyrosine kinase receptor (FGFR1) act through a very complex network of mechanisms and pathways. In this work we have
evaluated the antiproliferative activity effect of PD166866, a synthetic molecule inhibiting the tyrosin kinase action of FGFR1.
Methods: Cells were routinely grown in Dulbecco Modified Eagle's medium supplemented with newborn serum and a penicillin-
streptomycin mixture.
Cell viability was evaluated by Mosmann assay and by trypan blue staining. DNA damage was assessed by in situ fluorescent
staining with Terminal Deoxynucleotidyl Transferase dUTP nick end labeling (TUNEL assay).
Assessment of oxidative stress at membrane level was measured by quantitative analysis of the intra-cellular formation of
malonyl-dialdheyde (MDA) deriving from the decomposition of poly-unsaturated fatty acids.
The expression of Poly-ADP-Ribose-Polymerase (PARP), consequent to DNA fragmentation, was evidenced by immuno-
histochemistry utilizing an antibody directed against an N-terminal fragment of the enzyme.
Results: The bioactivity of the drug was investigated on Hela cells. Cytoxicity was assessed by the Mosmann assay and by vital
staining with trypan blue. The target of the molecule is most likely the cell membrane as shown by the significant increase of the
intracellular concentration of malonyl-dihaldheyde. The increase of this compound, as a consequence of the treatment with
PD166866, is suggestive of membrane lipoperoxidation. The TUNEL assay gave a qualitative, though clear, indication of DNA
damage. Furthermore we demonstrate intracellular accumulation of poly-ADP-ribose polymerase I. This enzyme is a sensor of
nicks on the DNA strands and this supports the idea that treatment with the drug induces cell death.
Conclusions: Data presented in this work show that PD166866 has clear antiproliferative effects. The negative control of cell
proliferation may be exerted through the activation of the apoptotic pathway. The results of experiments addressing this specific
point, such as: evaluation of DNA damage, lipoperoxidation of the cell membrane and increase of expression of PARP, an enzyme
directly involved in DNA repair. Results suggest that cells exposed to PD16866 undergo apoptosis. However, concomitant
modes of cell death cannot be ruled out. The possible use of this drug for therapeutic purposes is discussed.
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The dys-regulation of growth factor expression leads to
alterations of cell functions such as growth control and
proliferation [1,2]; as a matter of fact the role of these fac-
tors as well as that of their tyrosine kinase receptors in
growth regulation is now a well established notion. This
action is exerted through a myriad of mechanisms and
pathways and their involvement in biological processes
ranging from differentiation to apoptosis has been amply
demonstrated [3-6].
The aim of this work was to evaluate the effect of a syn-
thetic molecule, PD166866, which is an inhibitor of the
tyrosine kinase function exerted by FGFR1. In addition to
PD166866 other tyrosine kinase inhibitor molecules,
such as SU 4984 and SU 5402 have been described. These
compounds show a very high selectivity towards FGFR1
and inhibit the auto-phosphorylation activity of FGRF1,
however PD166866 shows an about 100-fold higher
activity [7]. Other biological activities have been ascribed
to these compounds and it is generally accepted that they
may find a possible application for the control of prolifer-
ation both of normal and tumor cells [8-10]. The results
presented here extend a previous study where the activity
of PD166866 was assayed on a normal murine fibroblast
cell line in culture [10]. The impact of this drug on the
overall cell metabolism was also investigated in a previous
work from our laboratory [11].
Here we evaluate the bioactivity of the drug versus a
human tumor cell line (HeLa). The growth inhibition
monitored in this study strongly suggests that it may
derive from DNA damage and activation of cell death
processes most likely of apoptotic nature. Therefore a
future clinical use for the control of proliferative patholo-
gies may be envisaged.
Methods
Growth and maintenance of HeLa cells
Cells were maintained in DMEM (Dulbecco's Modified
Eagle's Medium - high glucose), supplemented with new-
born bovine serum [final concentration (f.c.) 10%], peni-
cillin-streptomycin (10000 U/ml) and glutamine (2 mM);
the pH of the medium was 7.2 and incubation was at
37°C in a 5% CO2 atmosphere. Cells were routinely pas-
saged when confluent.
Assessment of cell viability and lipoperoxidation assay
Cell viability was evaluated by the colorimetric Mosmann
assay [12] which is a quantitative method measuring the
level of mitochondrial damage. The MTT [3-(4,5-
dimetiltiazol-2-yl)-2,5-difenil tetrazolium-bromide] is a
yellow water soluble salt which is converted into insolu-
ble purple salts formed by the active dehydrogenases
present in the mitochondria of vital cells. Absorbance val-
ues measured at 570 nm provide the number of vital cells.
The cell survival data were validated by vital staining with
trypan blue performed by a standard laboratory protocol.
A commercial kit (LPO-586; Oxis Health Research Prod-
ucts Portland, Or. USA) was used to assess the oxidative
stress at membrane level. Briefly, the assay is based on a
quantitative analysis of the intra-cellular formation of
malonyl-dialdheyde (MDA) which derives from the
decomposition of poly-unsaturated fatty acids. The MDA
molecule reacts with a chromogenic compound (N-
methyl-2-phenylindole) thus forming a stable chromo-
phore. Absorbance at 586 nm is directly transformed in
intracellular concentration of MDA [13].
TUNEL assay and analysis of the DNA fragmentation
The activation of the endogenous DNases is one of the
consequences of cell death causing the formation of single
strand nicks and eventually fragmentation of DNA. The
DNA ruptures may be evidenced by in situ labelling. Cell
nuclei are permeabilized, fluorescent dUTP is added and
terminal-deoxynucleotide-transferase conjugates the
nucleotide where the sugar-phosphate backbone is inter-
rupted. Fluorescence intensity provides a qualitative idea
of DNA damage [14].
Immunolocalization of Poly-ADP-Ribose-Polymerase 
(PARP)
The enzyme PARP is activated in response to DNA frag-
mentation. The immunolocalization of PARP was per-
formed as previously published [15]. Briefly, HeLa cells
were treated with PD166866 for 24 hours, the growth
medium was removed, the cells were washed with PBS
and fixed for 1 hour at 25°C adding a freshly made para-
formaldheyde solution (4% in PBS). Samples were
washed again with PBS and the endogenous oxidases were
blocked for 2 minutes in the dark. Further washes with
PBS followed and blocking the unspecific sites was done
for 1 hour at 25°C. PARP was evidenced by immunolocal-
ization utilizing a polyclonal antibody (PARP H-250
Santa Cruz Biotechnology, Inc.), directed against the N-
terminal proteolytic fragment. Immuno-reaction was
revealed by a secondary anti-rabbit antibody after incuba-
tion for 16 hours at 4°C. After exhaustive washing with
PBS the samples were incubated for 30 minutes in solu-
tion ABC (Vectastain ABC-POD Elite, PK-6101 kit, used
according the supplier's recommendations). Eventually,
DAB (3,3'-Diaminobenzidine) was added and the sam-
ples were incubated for 10 minutes in the dark. The sam-
ples were washed again the plates were sealed and ready
for microscopic observation (Zeiss Axiophot).
Statistical analysis
Data were obtained by at least three independent experi-
ments. Statistical analysis was done by one way analysis ofPage 2 of 6
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(Least Significant Difference). Results were considered sig-
nificant when p < 0.05.
Results
Cytotoxicity of PD166866 on HeLa cells in culture
We explored the dose/response effect of HeLa cells
exposed to a relatively broad range of PD166866 concen-
trations (0.1 - 50 μM). Cells were treated for 24 hours with
the drug and their vitality assessed by the MTT assay [12].
A significant reduction of vital cells can be monitored
already at 2.5 μM concentration (Figure 1, left panel). The
loss of viability seems to stabilize at 25 μM (about 25%
survival) with no further decrease at a 50 μM concentra-
tion of drug. This result may indicate the presence of a cell
subpopulation, intrinsically resistant to the drug. This
result was confirmed by vital cell count with trypan blue
(only the data obtained at 2.5 μM of drug is shown; Figure
1, right panel). The negative effect of PD166866 on the
cell growth was already observed in a previous works per-
formed on 3T6 cells: a stabilized murine fibroblast line
[10,11]. The results presented here validate those already
published and, as far as cell survival is concerning, no dif-
ference can be monitored on HeLa in comparison to 3T6
cells in matching experiments also run in this work (not
shown). Interestingly, as observed in a former study, HeLa
cells showed a significantly higher sensitivity than murine
cells towards resveratrol, a natural product showing both
cytotoxic and antiviral properties [16]. One way to ration-
alize this data is that the cellular/molecular target of the
two drugs could be different.
The Mosmann assay [12] indicates membrane damage,
essentially at mitochondrion level. Therefore, we investi-
gated the possibility that PD166866 may be detrimental
to the membrane integrity by lipoperoxidation assays
[13].
Lipoperoxidation shows that PD166866 causes membrane 
damage
The lipoperoxidation assay is a very powerful tool to eval-
uate in a quantitative manner the membrane damage
deriving from phenomena of oxidative stress. The forma-
tion of poly-unsaturated acids, consequent to this stress,
causes the formation malonyl-dihaldeyde (MDA) and of
4-hydroxyhalkenals. The concentration of intracellular
MDA, a compound normally not found in the cytoplasm,
is correlated directly to the extent of the membrane dam-
age [13]. In this experiment we treated the cells with
PD166866 (50 μM) or with H2O2 which, like other oxy-
gen reactive species is a very well known inducer of oxida-
tive stress in animal and plant cell as well as in diverse
pathologies [17-19].
The results of Figure 2 (central bar) show that that treat-
ment with the drug causes an over 4-fold increase of the
intracellular concentration of MDA: thus PD166866
induces an oxidative stress with consequent membrane
damage. However, one should not be misled by the much
higher level of MDA generated by H2O2 (Figure 2 left bar)
since the concentration and the power of this compound
is by no means comparable with that of PD166866 in this
experimental context. Finally, it is known that an uncon-
trolled oxidative stress may lead to apoptotic cell death
Assessment of cell survival after treatment with PD166866Figure 1
Assessment of cell survival after treatment with PD166866. Cells were treated with PD166866 for 24 hours at the 
indicated concentrations. At the end of the treatment, the samples were subjected to the Mossman assay (right panel). Alter-
natively after treatment cells were stained with trypan blue according to standard laboratory procedures (left panel). In this lat-
ter case only the survival at 2.5 μM is reported.Page 3 of 6
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diagnostic of apoptosis: DNA damage.
DNA damage and cell death assessed by fluorescent 
TUNEL staining
The TUNEL assay is an experimental protocol allowing the
detection of DNA fragmentation. The specificity of this
assay has been disputed but modifications done to the
original method [21] improved its accuracy [22]. There-
fore, it is generally accepted that the correct execution of
the TUNEL protocol mainly labels DNA fragmentation in
very advanced phases of apoptosis [23,24] thus evidenc-
ing cells that have sustained severe DNA damage.
The cells were treated with PD166866 in the usual exper-
imental conditions (50 μM for 24 hours). Results show a
very evident fluorescent staining of the cells treated with
the drug (Figure 3, large panel) which is a sign of extensive
DNA rupturing. In the positive control, cells treated with
H2O2 also a very diffuse fluorescence is visible (Figure 3,
left small panel). On the contrary, little if any fluorescence
is monitored in control plates (Figure 3, right small
panel). Therefore we can conclude that in cells treated for
24 hours with PD166866 the apoptotic pathway is in
progress.
Poly-ADP-Ribose-Polymerase (PARP) is accumulated after 
treatment with PD166866
The nuclear enzyme PARP-1 catalyzes the transfer and
binds ADP-ribose polymers to itself and other nuclear
proteins in response to interruptions of the DNA phos-
Intracellular concentration of malonyl-dihaldehyde (MDA) af er treatment with PD166866Figur  2
Intracellular concentration of malonyl-dihaldehyde 
(MDA) after treatment with PD166866. Cells were 
treated with the drug (50 μM) for 24 hours and processed 
for the membrane lipoperoxidation test. The intracellular 
concentration of MDA is over 4-fold higher in cells treated 
with the drug (central bar) as compared to untreated control 
cells (left bar). This indicates membrane damage due to oxi-
dative stress.
An extensive DNA damage is caused by treatment with PD166866Figure 3
An extensive DNA damage is caused by treatment 
with PD166866. After treatment with the drug (50 μM for 
24 hours), the cell nuclei were permeabilized. Fluorescent 
dUTP and terminal-deoxynucleotide-transferase were added. 
The enzyme conjugates the nucleotide where the sugar-
phosphate backbone is interrupted. The high intensity of flu-
orescence (large panel) indicated of extensive DNA damage 
due to the exposure to the drug. This is also monitored in 
cells treated with H2O2 (small left panel), while it is virtually 
absent in untreated control cells (small right panel).
Accumulation Poly-ADP-Ribose-Polymerase (PARP) in cells treated with PD166866 ev denced by imuno-histochemistryFig re 4
Accumulation Poly-ADP-Ribose-Polymerase (PARP) 
in cells treated with PD166866 evidenced by imuno-
histochemistry. Cells were treated with the drug (50 μM 
for 24 hours) and processed by immuno-histochemical tech-
niques to visualize the intracellular accumulation of PARP. 
The dark nuclei indicate accumulation of this enzyme in 
treated cells (large panel). The immuno-reaction also occurs 
in positive control cells treated with H202 (left small panel) 
while it is almost absent in untreated control cells. These 
results indicate cell death.Page 4 of 6
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the cleavage of PARP-1 into two fragments and this has
become a general hallmark of apoptosis [25-29].
Results of Figure 4 (large panel) show a relevant immuno-
positivity to PARP-1 in cells treated with PD166866 (24
hours 50 μM) which is also monitored in positive control
cells where apoptosis was caused by the administration of
H2O2 (upper left panel). The overall conclusion is that the
cells treated with the drug are found actually in a condi-
tion of advanced apoptosis.
Discussion
The family of Growth Factor Receptors (FGFR) is consti-
tuted by tyrosine kinases involved in a number of differ-
ent cell functions ranging from cell growth control to
mytogenesis and differentiation. Consequently, the inter-
ruption of the tyrosine-kinase signal transduction is con-
sidered a powerful strategy to inhibit angiogenesis and
tumor cell proliferation: therefore fibroblast growth fac-
tors and their high-affinity receptors play a crucial role for
cell growth survival and maintenance. The interplay
between growth factors and their receptors is indeed a very
complex one; however, the overall emerging picture is
that PD166866, as a tyrosine kinase inhibitor, is able to
invalidate the protective action exerted by different agents
inducing apoptosis [30,31]. In any case, inhibition of the
FGF receptors mediated by small molecules such as
SU5402 and PD166866 have been recently shown to
reduce growth, survival and motility, as well as clonogenic
potential in non small cancer lung cell lines (SSCLC) [32].
The data reported here indicate that one of the cellular tar-
gets of the drug may be the membrane of the HeLa cells
which is agreement with the membrane localization of
the FGFR. The treatment with PD166866 apparently
causes a mitochondrial deficit and an oxidative stress, as
demonstrated respectively, by the MTT assay and by the
increase of the intracellular concentration of malonyl-
dihaldeyde. However, rationalizing how the drug could
activate these processes is not an easy task. In any case, the
impact of PD166866 on the overall cell metabolism [11]
cannot be disregarded as an element of serious perturba-
tion of the cell homeostasis. It may be argued that apop-
tosis could not be the only death process activated by
PD166866. Concerning this particular aspect, the role of
PARP in executing the cell death program should be dis-
cussed in more detail. In our immunoblotting experi-
ments, PARP-1 was revealed by an antibody directed
towards N-terminal fragment of the enzyme thus indicat-
ing that proteolytic cleavage, mediated by caspases, actu-
ally occurs in our experimental model: therefore DNA
repair operated by PARP cannot longer occur and the cells
exposed to PD166866 proceed into the apoptotic death.
However, it has been shown that in necrotic death, cleav-
age of PARP-1 is caspase resistant and its proteolysis is
partly or totally caused by lysosomal proteases [33]. Also
PARP is not proteolytically cleaved by caspases during
apoptosis in hepatocytes [34]. A recent literature report
demonstrated that cell death may occur in a caspase-inde-
pendent manner (CICD, Caspase Independent Cell
Death) also defined as necroptosis [35]. Finally, a further
form of cell death has been described recently which is
distinct from apoptosis, necrosis, or autophagy and is
termed parthanatos. This is a PARP-1-dependent ubiqui-
tarious form of cell death involved in all tissues of the
organism and in pathologies as diverse as Parkinson's dis-
ease, stroke, heart attack, diabetes, and ischemia [36].
The overall conclusion drawn from the evidence pre-
sented here is that cells treated with PD166866 mainly die
by apoptosis; however the possibility that different forms
of cell death may occur contemporarily should be also
taken into account. In any case, apart from the mode of
death, the results discussed in this work corroborate the
idea that PD166866 is able to control in a negative fash-
ion the cell proliferation. With respect to this, the most
interesting aspect of the work is that PD166866 is able to
inhibit the proliferation of cultured human tumor cells.
Conclusions
The results presented here show that the synthetic mole-
cule PD166866 has significant anti-proliferative effects.
These data were obtained by the colorimetric assay of
Mosmann and further validated by vital cell count after
trypan blue dying. The TUNEL assay allowed a qualitative
assessment of DNA damage which could be one of the
reasons leading to cell death: however the possibility of
this fluorescent staining to discriminate between apopto-
sis and necrosis has been long discussed. Therefore we
ascertained the type of cell death by immunoprecipitation
assays of PARP, enzyme an involved in DNA repair whose
expression is enhanced during apoptosis. The extensive
immunopositivity monitored in the samples treated with
PD166866 allows us to conclude that this drug causes cell
death possibly via the activation of the apoptotic path-
way, even though other forms of cell death cannot be
ruled out. In addition, the results of the lipoperoxidation
assays, which indicate an oxidative stress at membrane
level, suggest that this cell district could be a target for this
molecule. However, further studies are needed to assess
the antitumor potential of PD166866: in particular future
studies in vivo, in animal model systems, are required to
elucidate this aspect.
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